CorMedix Historical Financial Ratios
| CRMD Stock | USD 9.96 0.37 3.58% |
CorMedix is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0179, PTB Ratio of 2.87 or Days Sales Outstanding of 162 will help investors to properly organize and evaluate CorMedix financial condition quickly.
CorMedix |
About CorMedix Financial Ratios Analysis
CorMedixFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate CorMedix investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on CorMedix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across CorMedix history.
CorMedix Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing CorMedix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CorMedix sales, a figure that is much harder to manipulate than other CorMedix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is CorMedix dividend as a percentage of CorMedix stock price. CorMedix dividend yield is a measure of CorMedix stock productivity, which can be interpreted as interest rate earned on an CorMedix investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Debt To Equity
A measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets.Most ratios from CorMedix's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into CorMedix current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.At present, CorMedix's Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 1.45, whereas Free Cash Flow Yield is forecasted to decline to (0.21).
| 2023 | 2024 (projected) | Dividend Yield | 0.0202 | 0.0179 | Price To Sales Ratio | 3.0K | 1.6K |
CorMedix fundamentals Correlations
Click cells to compare fundamentals
CorMedix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CorMedix fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 620.71 | 887.07 | 896.33 | 2.6K | 3.0K | 1.6K | |
| Ptb Ratio | (0.9) | (0.98) | (0.7) | (0.62) | 2.73 | 2.87 | |
| Days Sales Outstanding | 9.26 | 0.0451 | 5.12 | 86.73 | 99.74 | 161.52 | |
| Book Value Per Share | 0.98 | 1.55 | 1.67 | 1.37 | 1.38 | 1.45 | |
| Operating Cash Flow Per Share | (0.62) | (0.77) | (0.56) | (0.61) | (0.75) | (0.79) | |
| Stock Based Compensation To Revenue | 8.61 | 10.45 | 26.41 | 62.22 | 71.55 | 90.23 | |
| Capex To Depreciation | 0.5 | 0.88 | 23.03 | 2.59 | 4.63 | 3.03 | |
| Pb Ratio | (0.9) | (0.98) | (0.7) | (0.62) | 2.73 | 2.87 | |
| Ev To Sales | 562.39 | 715.42 | 620.7 | 1.9K | 2.2K | 1.3K | |
| Free Cash Flow Per Share | (0.62) | (0.77) | (0.6) | (0.61) | (0.76) | (0.8) | |
| Roic | 0.16 | 0.0822 | 0.1 | 0.11 | (0.7) | (0.66) | |
| Inventory Turnover | 1.1 | 1.43 | 49.51 | 0.0976 | 0.0878 | 0.0834 | |
| Net Income Per Share | (0.68) | (0.77) | (0.75) | (0.74) | (0.91) | (0.96) | |
| Days Of Inventory On Hand | 331.0 | 255.81 | 7.37 | 3.7K | 3.4K | 3.5K | |
| Payables Turnover | 0.36 | 0.18 | 0.0674 | 0.001696 | 0.048 | 0.0456 | |
| Research And Ddevelopement To Revenue | 39.02 | 55.92 | 68.78 | 163.28 | 187.77 | 128.18 | |
| Cash Per Share | 1.18 | 1.63 | 1.75 | 1.47 | 1.49 | 2.51 | |
| Pocfratio | (11.68) | (9.66) | (8.09) | (6.95) | (4.98) | (5.23) | |
| Interest Coverage | (26.68) | (819.26) | (1.8K) | (1.2K) | (1.3K) | (1.4K) | |
| Capex To Operating Cash Flow | (0.00243) | (0.005127) | (0.0674) | (0.009006) | (0.008521) | (0.008947) | |
| Pfcf Ratio | (11.65) | (9.61) | (7.58) | (6.89) | (4.94) | (5.19) | |
| Days Payables Outstanding | 1.0K | 2.0K | 5.4K | 215.3K | 7.6K | 7.2K | |
| Income Quality | 0.92 | 1.0 | 0.75 | 0.82 | 0.83 | 0.56 | |
| Roe | 0.15 | 0.0841 | 0.1 | 0.11 | (0.66) | (0.63) | |
| Ev To Operating Cash Flow | (10.58) | (7.79) | (5.6) | (5.21) | (3.86) | (4.06) | |
| Pe Ratio | (10.7) | (9.63) | (6.07) | (5.7) | (4.13) | (4.34) | |
| Return On Tangible Assets | (1.43) | (0.56) | (0.45) | (0.41) | (0.48) | (0.59) | |
| Ev To Free Cash Flow | (10.56) | (7.75) | (5.25) | (5.16) | (3.83) | (4.02) | |
| Earnings Yield | (0.0935) | (0.1) | (0.16) | (0.18) | (0.24) | (0.25) | |
| Net Debt To E B I T D A | 0.8 | 1.52 | 1.79 | 1.42 | 0.88 | 0.92 | |
| Current Ratio | 5.04 | 11.58 | 12.44 | 9.44 | 6.97 | 4.32 | |
| Tangible Book Value Per Share | 0.98 | 1.55 | 1.67 | 1.37 | 1.38 | 1.45 | |
| Receivables Turnover | 39.42 | 8.1K | 71.26 | 4.21 | 3.79 | 3.6 | |
| Graham Number | 11.13 | 11.49 | 10.5 | 10.69 | 5.31 | 5.05 | |
| Shareholders Equity Per Share | (8.09) | (7.61) | (6.53) | (6.86) | 1.38 | 1.45 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.